Načítá se...
Validating cancer drug targets through chemical genetics
Targeted therapies for cancer promise to revolutionize treatment by specifically inactivating pathways needed for the growth of tumor cells. The most prominent example of such therapy is imatinib (Gleevec), which targets the Bcr-Abl kinase and provides an effective low-toxicity treatment for chronic...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3028588/ https://ncbi.nlm.nih.gov/pubmed/20708654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbcan.2010.08.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|